Obesity Clinical Trial
— [PTREC]Official title:
Effects of High-Intensity Interval and Moderate Intensity Continuous Exercise on Diabetic Obese Patients With Nonalcoholic Fatty Liver Disease- A Comparative Randomized Controlled Trial
Verified date | June 2020 |
Source | Ahlia University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
background: Obesity, diabetes mellitus type II and fatty liver disease combining with low levels of physical activity are prominent health risks for mortality and morbidity. More than 1/3 of the current population is suffering from obesity with a significant proportion to medical complications which can negatively influence their quality of life. These complications comprise alterations of the metabolism of glucose and fat, insulin resistance and diabetes mellitus. Objectives The purpose of this study was to compare between high intensity interval exercise and moderate intensity continuous on diabetic obese patients with NAFLD. Methods: forty-seven diabetic obese individuals with NAFLD were enrolled in this study. The individuals were randomly divided into 16 in HII group, 15 in MIC group, and 16 in the controls. HII group received HII exercise, MIC group received 8-week MIC exercise while the control group did not receive any exercise intervention. IHTG and visceral lipids were assessed pre- and post-intervention.
Status | Completed |
Enrollment | 48 |
Est. completion date | December 10, 2018 |
Est. primary completion date | August 10, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 60 Years |
Eligibility |
Inclusion criteria: - Clinical diagnosis of NAFLD, type II DM, and obesity. - Body mass index (BMI) =30 kg/m2. - Age: 40-60 years - No smoking. Exclusion criteria: - Severe life limiting illness (cancer, renal failure), - Uncontrolled heart disease, - Neuromuscular limitations, - Orthopedic problems - Endocrine disorders that could affect physical exercise |
Country | Name | City | State |
---|---|---|---|
Egypt | Dr Sayed Tanatwy | Giza |
Lead Sponsor | Collaborator |
---|---|
Ahlia University | Cairo University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intrahepatic triglyceride (%) | Assessment in percentage (%) using MRI with a 3T scanner (General electric, WI) through imaging of chemical shift. Each patient was assessed for imaging in the supine position using the body coil. The patient was instructed to make a single breath hold during imaging, the liver was imaged 3 separate images slice pairs. IHTG proportionate to water was estimated as 100 × (signal amplitude of TG)/(signal amplitude of water). | 8 weeks | |
Primary | Total cholesterol | Total cholesterol, (mg/dL) | 8 weeks | |
Primary | Triglycerides | Triglycerides, (mg/dL) | 8 weeks | |
Primary | High-density lipoproteins (HDLs) | High-density lipoproteins (HDLs), (mg/dL) | 8 weeks | |
Primary | Low-density lipoproteins (LDLs) | Low-density lipoproteins (LDLs), (mg/dL) | 8 weeks | |
Primary | Alanine-transaminase (ALT) | Alanine-transaminase (ALT), (IU/L) | 8 weeks | |
Primary | Hemoglobin A1c (HbA1c) | Hemoglobin A1c (HbA1c), (%) | 8 weeks | |
Primary | Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | It was assessed through Blood Code Calculation: HOMA-IR = Insulin (mU/L) ? Glucose (mg/dL). |
8 weeks | |
Secondary | Weight | Weight (kilograms Kg) Alanine-transaminase (ALT), (IU/L) Visceral adipose fat, (cm2) was assessed by MRI and anthropometric values. Body mass index (BMI) in Kg/m2 was calculated as the weight (in kilograms) divided by height (in meters) squared. |
8 weeks | |
Secondary | Height | Height (meters m) | 8 weeks | |
Secondary | Body mass index (BMI) | Weight and height were combined to report BMI in kg/m^2 | 8 weeks | |
Secondary | Visceral adipose fat | Visceral adipose fat, (cm2) was assessed by MRI and anthropometric values. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |